The global Extracorporeal Membrane Oxygenation (ECMO) market was valued at USD 290.2 Million in 2023 and is expected to reach USD 385.9 Million by the year 2032, at a CAGR of 3.6%. Extracorporeal membrane oxygenation (ECMO) is a life support device used in the patients with failed lungs, and heart fails to pump sufficient blood to the body.
Rising the prevalence of cardiovascular and respiratory diseases across the globe is one of the major driver propelling the market growth. For instance, in U.S. over 18.2 million suffer from coronary artery disease; that contributes to annual healthcare expenditure of approximately USD 219 billion. Growing aged population and obesity worldwide are the primary cause leading to raised cases of coronary heart diseases. Furthermore, common medical conditions such as diabetes, anxiety, high blood pressure, and high cholesterol are reflected frequently among the old population which would potentially increase the risk of heart related diseases leading to increasing demand of device for arterial respiration. The market for ECMO is expected to surge with proliferating geriatric population across the globe, where, Europe and North America have the highest share of population with age of over sixty-five years and above. Additionally, emerging applications of ECMO for COVID-19 infections is also expected to provide dramatic boost to the adoption of the technology and its demand across the globe.
Increasing ECMO centers across the globe is reflects increasing adoption of the device in developed nations. As of 2023 approximately 400 hospitals in the U.S. provides ECMO, and is estimated to grow in the forecasted year. Adoption of new technologies such as coating the ECMO surface with synthetic and natural polymers that prevented the binding of platelets and leukocytes is expected to enhance the safety and efficacy of this technology. However high cost of the procedure may hinder the extracorporeal membrane oxygenation market growth in various parts of the world.
The COVID-19 Impact:
The sudden outbreak of COVID-19 has reported a significant inclination in the Extracorporeal Membrane Oxygenation (ECMO) market growth. As COVID-19 can trigger acute respiratory failure and/or acute cardiopulmonary failure, the FDA has stated the new policy for the treatment of COVID-19 patients, to allow usage of ECMO for longer durations. With the shortage of ventilators and a rising number of cases, it is only a matter of time before there is an increased need for ECMO to ensure the survival of critically ill patients. In March 2023, a Phoenix man was on the brink of death with a ventilator became the first patient to survive COVID-19 patient through extracorporeal membrane oxygenation (ECMO) therapy. As of 15th April 2023, number of COVID-19 cases in ECMO are 230, 89, 14 and 9 in North America, Europe, Asia-Pacific and Latin America, respectively.
According to a survey, Covid-19 cases in the U.S. continues are increasing by 41% every day. Approximately 32,000-12,000 American COVID infected patients are expected to require extracorporeal machine oxygenation (ECMO). ECMO machines have successfully proven an effective treatment of COVID-19 in several countries outside of the U.S., such as China, South Korea, and Japan. In Japan, around 100 COVID-19 infected patients have received life-support treatment via ECMO machines. However, due to higher raw material costs, disrupted supply chain, and restricted transportation with higher excise duties, many economies are facing product shortage. To serve the smooth supply to the raised demand, the U.S. Food and Drug Administration (FDA) has issued guidance to provide a policy to help expand the availability of devices used in extracorporeal membrane oxygenation (ECMO) therapy to address the novel coronavirus public health emergency. The FDA has included a list of all the devices that are capable of being used for ECMO therapy to be used for the treatment of COVID-19 patients. This policy is intended to remain in effect only for the duration of the public health emergency related to COVID-19. As the global COVID cases surpassed line of 2 million cases, lifesaving technologies such as ECMO is expected to boom. Furthermore, even after the COVID-19 pandemic is curbed, the demand for such devices is expected to continue to grow at a high pace, as the new world will like to be prepared to future possibilities of epidemics.
Salient Features of the Extracorporeal Membrane Oxygenation Market
Companies Considered and profiled in this market study
Getinge Group (Sweden), Medtronic plc (Ireland), LivaNova PLC (U.K.), XENIOS AG (Germany), Terumo Corporation (Japan), MicroPort Scientific Corporation (China), NIPRO Corporation (Japan), OriGen Biomedical, Inc. (U.S.), ALung Technologies, Inc. (Germany), and EUROSETS S.r.l. (Italy).
Key Coverage of the Report
This report predicts revenue growth and CAGR at a global, regional & country level, and analyses the markets by studying the drivers, constraints, opportunities, threats, challenges, Investment opportunities, products, uses, trends, market shares in each of the sub-segments from 2023 to 2032. For the purpose of this study have segmented the global Extracorporeal Membrane Oxygenation (ECMO) market report based on type, component, application, end use and region:
Type Outlook (Revenue, USD Million; 2023-2032)
Component Outlook (Revenue, USD Million; 2023-2032)
Application Outlook (Revenue, USD Million; 2023-2032)
End Use Outlook (Revenue, USD Million; 2023-2032)
Regional Outlook (Revenue in USD Million; 2023-2032)